Humacyte (HUMA) stock

Market cap $145MShares as of Aug 10

$0.52
+3.70%

Market closed. Prices as of Friday's close.

Not scored

Breakaway doesn't score HUMA. It is priced too low for a fair Quality Score.

Healthcare · Biotech

Next2H 2026“…Humacyte plans to submit a supplemental Biologics License Application to the FDA in the second half of 2026…”Filing with regulators · 8-K, Aug 12
Cash$79.9M, about 3 quarters at the last year's spendingOn Jun 30

Follow HUMA's trial news. Pro members can get an alert when Humacyte files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when HUMA files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.
Cash$79.9M, about 3 quarters at the last year's spendingOn Jun 30

We do the work for you. 3,243 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live. So can you, free, with no account.

What's next for HUMA, and how long its cash lasts

From Humacyte’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“Based on these results, Humacyte plans to submit a supplemental Biologics License Application to the FDA in the second half of 2026.”Filing with regulators · 8-K, Aug 12

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisPhase 3 · Active · 121 people · main data estimated Jun 2027 · NCT05908084

3 more trials, 42 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 3 quarters

$79.9M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Sep 12, 2025)
  • At-the-market share sales program (424B5, filed Dec 16, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 9 raises and their amounts, and the share count against a year ago.

Insiders

Director Keith Anthony Jones bought 10,000 shares on Sep 14. 6 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade, and Laura Niklason’s 7 filings and quotes.

Get an optional alert when HUMA files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

HUMA's latest filings

33 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why HUMA isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. HUMA trades at $0.52. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price on this page is delayed at least 15 minutes. The share count and the filings are shown as filed.